While the patent on the chemical drug expired in 2015, Teva obtained new US patents covering pharmaceutical formulations for long-acting delivery. Litigation from industry competitors in 2016-2017 resulted in the new patents being judged invalid.
Teva retained rights to its chemical drug after its patent expired in 2015, but obtained new US patents for long-lasting pharmaceutical formulations. However, a lawsuit by competitors in 2016-2017 resulted in the new patents being declared null and void.